Mimedx (MDXG) Non Operating Income (2014 - 2026)
Mimedx recorded quarterly Non Operating Income of -$168000.0 in Q1 2026, up 9.68% quarter-over-quarter from -$186000.0 in Q4 2025, and down 15.86% year-over-year from -$199672.1 in Q1 2025.
Mimedx's Non Operating Income history runs 12 years deep, the most recent figure standing at -$168000.0 for Q1 2026.
- In Q1 2026, Non Operating Income fell 15.86% year-over-year to -$168000.0; the TTM figure through Mar 2026 stood at -$581000.0 (up 4.91% YoY), while the FY2025 annual figure was -$558000.0, up 1.24% from the prior year.
- Non Operating Income came in at -$168000.0 for Q1 2026 at Mimedx, up from -$186000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $16000.0 in Q4 2023 to a low of -$237000.0 in Q2 2024.
- A 5-year average of -$94214.3 and a median of -$100000.0 in 2024 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income soared 633.33% in 2023 and sank 5050.0% in 2024, its largest moves.
- Mimedx's Non Operating Income stood at -$3000.0 in 2022, then jumped by 633.33% to $16000.0 in 2023, then sank by 1400.0% to -$208000.0 in 2024, then climbed by 10.58% to -$186000.0 in 2025, then grew by 9.68% to -$168000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$168000.0, -$186000.0, and -$126000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | -168,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -168,000.00 |
| Dec 31, 2025 | -186,000.00 |
| Sep 30, 2025 | -126,000.00 |
| Jun 30, 2025 | -101,000.00 |
| Mar 31, 2025 | -145,000.00 |
| Dec 31, 2024 | -208,000.00 |
| Sep 30, 2024 | -21,000.00 |
| Jun 30, 2024 | -237,000.00 |
| Mar 31, 2024 | -99,000.00 |
| Dec 31, 2023 | 16,000.00 |
| Sep 30, 2023 | -11,000.00 |
| Jun 30, 2023 | -32,000.00 |
| Mar 31, 2023 | 2,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Dec 31, 2021 | -20,000.00 |
| Jun 30, 2021 | -3,000.00 |
| Dec 31, 2020 | -1,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Jun 30, 2020 | -9,000.00 |
| Mar 31, 2020 | 6,000.00 |
| Dec 31, 2019 | 11,000.00 |
| Sep 30, 2019 | 127,000.00 |
| Jun 30, 2019 | 174,000.00 |
| Mar 31, 2019 | -29,000.00 |
| Dec 31, 2017 | 337,000.00 |
| Sep 30, 2017 | -43,000.00 |
| Jun 30, 2017 | -149,000.00 |
| Mar 31, 2017 | -145,000.00 |
| Dec 31, 2016 | -85,000.00 |
| Sep 30, 2016 | -87,000.00 |
| Jun 30, 2016 | -111,000.00 |
| Mar 31, 2016 | -56,000.00 |
| Sep 30, 2015 | -5,000.00 |
| Jun 30, 2015 | 1,000.00 |
| Mar 31, 2015 | -14,000.00 |
| Sep 30, 2014 | -9,000.00 |
| Jun 30, 2014 | -8,000.00 |